Research programme: antidiabetic therapeutics - Dongkook pharmaceuticals
Latest Information Update: 14 Sep 2022
At a glance
- Originator Dongkook Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 02 Sep 2022 Preclinical trials in Diabetes mellitus in South Korea (unspecified route) (Dongkook pharmaceuticals pipeline, September 2022)